Company Update - Aprea Therapeutics has engaged Dr Philippe Pultar as its senior medical advisor to support the development and advancement of APR-1051, a potential best-in-class WEE1 inhibitor [1] - Dr Pultar brings extensive experience in oncology, including the development of a WEE1 inhibitor (azenosertib) from early to late-stage clinical development [2] - Dr Pultar's prior role at Zentalis Pharmaceuticals involved strategy and execution of the global clinical development of azenosertib, a WEE1 inhibitor [2] Clinical Development - Patient enrollment is ongoing in the Phase 1 ACESOT-1051 study, which assesses the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of APR-1051 in advanced solid tumors with certain cancer-associated gene alterations [3] - Aprea plans to provide an update on the progress of the ACESOT-1051 clinical study by the end of 2024 [3] - The WEE1 program is part of Aprea's portfolio of DDR-targeted therapeutics aimed at delivering precision medicine solutions [3] Leadership and Expertise - Dr Pultar has over 17 years of experience in early and late-stage clinical development, including roles at Zentalis Pharmaceuticals, Novartis Oncology, Agennix AG, and ImClone Systems [5] - Dr Pultar initiated seven Phase 1 and Phase 2 trials with azenosertib as a single agent and in combination with chemotherapy and targeted agents across multiple indications [5] - Dr Pultar's foundational education includes Medical Studies and Residency at Université de Médecine de Poitiers, France [6] Strategic Vision - Dr Pultar believes WEE1 inhibition is a promising therapeutic approach in oncology and is impressed by the progress of APR-1051, which has a differentiated profile and compelling pre-clinical data [4] - Aprea's President and CEO, Dr Oren Gilad, highlights Dr Pultar's track record of successfully leading programs through late-stage development and regulatory approval [4] - Dr Pultar's addition aligns with Aprea's strategy to bring in exceptional talent to advance its programs and maximize the therapeutic potential of APR-1051 [4] Leadership Transition - Dr Nadeem Mirza will step down as Chief Medical Officer effective October 9, 2024, but will remain with the company until no later than December 13, 2024, to ensure a smooth transition [4]

Company Performance - Aprea Therapeutics reported a quarterly loss of $0.58 per share, better than the Zacks Consensus Estimate of a loss of $0.64, and an improvement from a loss of $0.87 per share a year ago, indicating a 33.33% year-over-year improvement [1] - The company achieved a revenue of $0.56 million for the quarter, surpassing the Zacks Consensus Estimate by 462%, compared to $0.25 million in the same quarter last year [1] - Over the last four quarters, Aprea Therapeutics has exceeded consensus EPS estimates three times and topped consensus revenue estimates two times [1] Market Outlook - Aprea Therapeutics shares have declined approximately 28.5% since the beginning of the year, contrasting with the S&P 500's gain of 12% [2] - The current consensus EPS estimate for the upcoming quarter is -$0.65 on revenues of $0.15 million, and for the current fiscal year, it is -$2.57 on revenues of $0.8 million [4] Industry Context - The Medical - Biomedical and Genetics industry, to which Aprea Therapeutics belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable industry outlook [5] - Precigen, Inc., another company in the same industry, is expected to report a quarterly loss of $0.09 per share, reflecting a year-over-year change of -12.5%, with revenues anticipated to be $1.28 million, down 27.7% from the previous year [5][6]

[Executive Summary](index=1&type=section&id=Executive%20Summary) Aprea Therapeutics presents its Q2 2024 performance, emphasizing clinical trial advancements and a strong cash position [Second Quarter 2024 Highlights](index=1&type=section&id=Second%20Quarter%202024%20Highlights) Aprea Therapeutics reported Q2 2024 results, initiating ACESOT-1051 Phase 1 trial with no myelosuppression and extending cash runway into Q4 2025 - Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051, with **no myelosuppression observed** in the first of eight planned cohorts at a sub-therapeutic dose[1](index=1&type=chunk) - The Company reported **$28.7 million in cash and cash equivalents** as of June 30, 2024[1](index=1&type=chunk) - Cash runway is extended into **Q4 2025**[1](index=1&type=chunk) [Business Update](index=1&type=section&id=Business%20Update) Aprea provides updates on its clinical pipeline progress and key corporate developments, including leadership changes [Clinical Pipeline Progress](index=1&type=section&id=Clinical%20Pipeline%20Progress) Aprea advances its clinical pipeline with APR-1051 and ATRN-119, targeting oncology with promising early clinical development [ACESOT-1051 (APR-1051, WEE1 Inhibitor)](index=1&type=section&id=ACESOT-1051%20(APR-1051,%20WEE1%20Inhibitor)) Details on the ACESOT-1051 Phase 1 trial for APR-1051, a WEE1 inhibitor, covering enrollment and anticipated readouts - APR-1051 is a potent and selective small molecule WEE1 inhibitor designed for greater clinical activity, especially in cancers with Cyclin E overexpression[2](index=2&type=chunk) - Enrollment commenced in June 2024 for the ACESOT-1051 Phase 1 clinical trial, with the first patient dosed without **dose-limiting toxicities or myelosuppression**[2](index=2&type=chunk) - Primary objectives of the Phase 1 study include measuring safety, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD/MAD), and recommended Phase 2 dose (RP2D)[2](index=2&type=chunk) - An update on clinical study progress is expected by **year-end 2024**, with open-label safety/efficacy data anticipated in **H1 2025**[3](index=3&type=chunk) - APR-1051 was featured in a virtual KOL event in **June 2024** and two posters at the **AACR annual meeting in April 2024**[3](index=3&type=chunk) [ABOYA-119 (ATRN-119, ATR Inhibitor)](index=2&type=section&id=ABOYA-119%20(ATRN-119,%20ATR%20Inhibitor)) Outlines the ABOYA-119 Phase 1/2a clinical trial for ATRN-119, an ATR inhibitor, detailing dose cohorts and protocol amendments - ATRN-119 is a potent and highly selective first-in-class macrocyclic ATR inhibitor, designed for patients with **DDR-related gene mutations**[4](index=4&type=chunk) - The ABOYA-119 Phase 1/2a clinical trial is ongoing as monotherapy in advanced solid tumors with DDR-related gene mutations, with **five dose cohorts completed**[4](index=4&type=chunk) - Aprea plans to amend the study protocol to add a group for **twice-daily ATRN-119 administration** and investigate food effect on drug absorption[4](index=4&type=chunk) - The ABOYA-119 Phase 1 readout is anticipated in **H1 2025**[4](index=4&type=chunk) - An update on the ongoing trial was featured in a poster at the **AACR Annual Meeting in April**[4](index=4&type=chunk) [Corporate Developments](index=2&type=section&id=Corporate%20Developments) Aprea strengthened its leadership with the appointment of Nadeem Q. Mirza as Chief Medical Officer, effective May 1, 2024 - **Nadeem Q. Mirza, M.D., M.P.H.** was appointed as Chief Medical Officer (CMO), effective **May 1, 2024**, to lead the Company's clinical pipeline development[5](index=5&type=chunk) [Financial Results](index=2&type=section&id=Financial%20Results) Aprea presents its financial performance, including balance sheet and statements of operations, detailing key changes [Balance Sheet Overview](index=2&type=section&id=Balance%20Sheet%20Overview) Aprea's cash and cash equivalents increased to $28.7 million by June 30, 2024, extending cash runway into Q4 2025, with decreased liabilities Consolidated Balance Sheet Highlights | Metric | June 30, 2024 ($) | December 31, 2023 ($) | Change ($) | Change (%) | | :-------------------------- | :------------ | :---------------- | :--------- | :--------- | | Cash and cash equivalents | $28,694,694 | $21,606,820 | $7,087,874 | 32.8% | | Total current assets | $29,559,786 | $22,521,095 | $7,038,691 | 31.3% | | Total assets | $29,964,587 | $22,650,174 | $7,314,413 | 32.3% | | Total current liabilities | $3,094,229 | $4,385,605 | $(1,291,376) | -29.4% | | Total liabilities | $3,094,229 | $4,385,605 | $(1,291,376) | -29.4% | | Total stockholders' equity | $25,559,295 | $16,953,506 | $8,605,789 | 50.7% | - The Company believes its cash and cash equivalents as of **June 30, 2024**, will be sufficient to meet operating expenses and capital expenditure requirements into **Q4 2025**[5](index=5&type=chunk) [Statements of Operations Overview](index=3&type=section&id=Statements%20of%20Operations%20Overview) Aprea reported a Q2 2024 operating loss of $3.8 million, driven by increased R&D and G&A expenses, with decreased net loss per share Consolidated Statements of Operations Highlights (Three Months Ended June 30) | Metric | Q2 2024 ($) | Q2 2023 ($) | Change ($) | Change (%) | | :-------------------------- | :------------ | :------------ | :--------- | :--------- | | Grant revenue | $561,574 | $249,688 | $311,886 | 124.9% | | Research and development | $2,557,679 | $2,202,657 | $355,022 | 16.1% | | General and administrative | $1,850,819 | $1,698,712 | $152,107 | 9.0% | | Total operating expenses | $4,408,498 | $3,901,369 | $507,129 | 13.0% | | Loss from operations | $(3,846,924) | $(3,651,681) | $(195,243) | 5.3% | | Net loss | $(3,470,052) | $(3,259,097) | $(210,955) | 6.5% | | Net loss per share (basic) | $(0.58) | $(0.87) | $0.29 | -33.3% | | Weighted-average common shares outstanding | 5,937,291 | 3,731,571 | 2,205,720 | 59.1% | - Research and development expenses increased by approximately **$0.35 million**, primarily due to the initiation of the ACESOT-1051 Phase 1 dose-escalation study in **Q2 2024**[6](index=6&type=chunk) - General and administrative expenses increased by approximately **$0.15 million**, primarily due to increased personnel costs, including severance expense[7](index=7&type=chunk) [Company Information](index=3&type=section&id=Company%20Information) Overview of Aprea Therapeutics, its forward-looking statements, and contact information for investors and media [About Aprea Therapeutics](index=3&type=section&id=About%20Aprea%20Therapeutics) Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, with lead programs ATRN-119 and APR-1051 - Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on **precision oncology through synthetic lethality**[8](index=8&type=chunk) - The Company's lead programs are **ATRN-119**, a clinical-stage small molecule ATR inhibitor, and **APR-1051**, an oral, small-molecule WEE1 inhibitor that recently entered the clinic[8](index=8&type=chunk) [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) Standard disclaimer on forward-looking statements, cautioning about inherent risks and uncertainties, with no obligation to update unless legally required - The press release contains "forward-looking statements" regarding study analyses, clinical trials, regulatory submissions, and projected cash position, based on current beliefs and expectations but involving risks and uncertainties[9](index=9&type=chunk) - These statements are subject to risks including the success, timing, and cost of ongoing and anticipated clinical trials, and readers are cautioned not to place undue reliance on them[10](index=10&type=chunk) - The Company undertakes no obligation to update such forward-looking statements for any reason, except as required by law[10](index=10&type=chunk) [Investor and Media Contacts](index=4&type=section&id=Investor%20and%20Media%20Contacts) Contact information for investor relations and media inquiries is provided for external communication - Investor contact: **Mike Moyer at LifeSci Advisors** (mmoyer@lifesciadvisors.com)[11](index=11&type=chunk) - Media contact: **Ignacio Guerrero-Ros, Ph.D., or David Schull at Russo Partners, LLC** (Ignacio.guerrero-ros@russopartnersllc.com, David.schull@russopartnersllc.com)[11](index=11&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 84-2246769 (State or other ...

Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 – no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose $28.7 million in cash and cash equivalents as of June 30, 2024 with cash runway extended into Q4 2025 DOYLESTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financ ...

DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL event to discuss APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor, on Monday, June 24, 2024 at 9:00 AM ET. To register, click here. The webinar will feature Joseph Vacca, PhD, Medicinal Chemistry Expert and Consul ...

APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represents a key advancement in Aprea's clinical pipeline DOYLESTOWN, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncolo ...

Core Insights - ATRN-119 is the first and only macrocyclic ATR inhibitor in clinical trials, showing best-in-class potential [1] - The ongoing ABOYA-119 clinical trial is on track to complete dose escalation and potentially generate initial human efficacy data in the second half of 2024 [1][4] - Safety Review Committee has approved the commencement of dosing at 800 mg once daily for Cohort 6, following positive safety and pharmacokinetic data from Cohort 5 [2][3] Clinical Trial Progress - A total of 17 patients have been enrolled across the first five cohorts with doses ranging from 50 mg to 550 mg once daily [3] - Preliminary signs of clinical benefit have been observed, with two patients achieving stable disease at different dose levels [3] - The Phase 1 dose escalation is expected to be completed by the fourth quarter of 2024, with the recommended Phase 2 dose anticipated in the first quarter of 2025 [4] Drug Characteristics - ATRN-119 is designed for patients with mutations in DNA damage response (DDR) pathways, addressing a high unmet medical need in oncology [4] - The drug has demonstrated a differentiated selectivity and toxicity profile compared to other ATR inhibitors [2][4] - Pharmacokinetic data indicate that systemic exposure increases with each dose level, with therapeutic plasma concentrations observed at doses of 550 mg and above [2][5]

Exhibit 99.1 Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in June 2024 First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human ef icacy data in 2H 2024 Company had four poster presentations at the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 84-2246769 (State or other ...